CSIMarket
 
Ascendis Pharma A  (ASND)
Other Ticker:  
 
 

Ascendis Pharma A's Customers Performance

ASND

 
ASND's Source of Revenues During the corresponding time, Ascendis Pharma A recorded revenue increase by 557.93 % year on year, While revenue at the Ascendis Pharma A's corporate clients

List of ASND Customers




for the same period Ascendis Pharma A recorded revenue increase by 557.93 % year on year,

List of ASND Customers




Ascendis Pharma A's Comment on Sales, Marketing and Customers





  News about Ascendis Pharma A Contracts

Ascendis Pharma Unveils YORVIPATH for Chronic Hypoparathyroidism, Evolving Treatment for Patients in Germany and Austria

Ascendis Pharma Launches 2nd TransCon Product: YORVIPATH Now Available in Germany and Austria for Adults with Chronic HypoparathyroidismCOPENHAGEN, Denmark - Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company specializing in the development of innovative therapies, has recently announced the commercial launch of its second TransCon product, YORVIPATH (palopegteriparatide). Specifically developed as a parathyroid hormone (PTH) replacement therapy, YORVIPATH is indicated for the treatment of adults suffering from chronic hypoparathyroidism. This groundbreaking therapy is now readily available to patients in Germany and Austria.Chronic hypoparathyroidism is a rare endocrine disorder characterized b...

Hope on the Horizon: Revolutionary Treatment for Achondroplasia Shows Remarkable Improvements in Children's Health and Quality of Life

Significant Health and Quality of Life Improvements Achieved in Children with Achondroplasia Treated for One Year with TransCon CNP (Navepegritide) at 100g/kg/weekCOPENHAGEN, Denmark, Dec. 20, 2023 - Ascendis Pharma A/S (Nasdaq:ASND), a leading biopharmaceutical company, has recently announced a series of groundbreaking findings from their Phase 2 clinical trial, ACcomplisH, demonstrating the significant health and quality of life improvements achieved in children with achondroplasia treated with TransCon CNP (Navepegritide) at a dosage of 100g/kg/week for one year. These new analyses provide a glimmer of hope for children suffering from this rare genetic disorder and could transform their lives for the bett...












ASND's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Ascendis Pharma A 8,408.53 57.31 -653.18 -
SUBTOTAL 0.00 0.00 0.00 -


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com